Pfizer

Shanghai Pharmaceuticals inks $3 billion in overseas contracts

Thursday, April 14, 2011 01:07 PM

Shanghai Pharmaceuticals will ink more than $3.06 billion worth of procurement contracts with 69 worldwide pharmaceutical companies this year, according to Global Times.

More... »

Tafamidis for TTR-FAP shows positive results

Wednesday, April 13, 2011 12:54 PM

Pfizer reported data from an open-label, 12-month extension study (Fx-006) of the pivotal phase II/III (Fx-005) trial. This extension study evaluated the long-term clinical outcomes of tafamidis, an oral, investigational compound being studied as a treatment for patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP), a rare and fatal neurodegenerative disease. These data showed that slowing of disease progression was sustained over 30 months.

More... »

Researchers reveal GR and depression link

Wednesday, April 13, 2011 12:38 PM

Scientists in the U.K. using human stem cells say they have discovered how certain antidepressants form new brain cells, according to a Reuters report.  This finding will help researchers develop more effective drugs for treating depression.

More... »

Durect reports Eladur phase II results in back pain

Tuesday, April 12, 2011 12:30 PM

Durect has released results from a phase II clinical trial in chronic low back pain for Eladur (Transdurr-Bupivacaine), Durect's investigational transdermal bupivacaine pain patch. This study was conducted by Durect's collaborator, King Pharmaceuticals, which is now owned by Pfizer. In this study of 263 patients suffering from chronic low back pain, the primary efficacy endpoint of demonstrating a positive treatment difference for the mean change in pain intensity scores from baseline to the mean of weeks 11 and 12 between Eladur as compared to placebo was not met.  Complete data analysis is ongoing.

More... »

Pfizer and Medivation reveal results from phase 3 trial of Dimebon

Monday, April 11, 2011 01:03 PM

Pfizer and Medivation reported results from the phase III HORIZON trial of the investigational drug dimebon (latrepirdine) in patients with Huntington disease. Dimebon did not achieve statistical significance for either of the co-primary endpoints, the Mini-Mental State Examination (MMSE), which measures cognition (p=0.39), or the Clinician's Interview-Based Impression of Change, plus caregiver input (CIBIC-plus), which measures global function (p=0.84).

More... »

MusclePharm adds Dr. Richard Ogden to board

Monday, April 11, 2011 12:37 PM

MusclePharm, a Nevada corporation, a U.S. nutritional supplement company, will add Richard Ogden, PhD, to its medical advisory board.

More... »

Zacharon Pharmaceuticals collaborates with Pfizer

Friday, April 8, 2011 10:40 AM

California-based Zacharon Pharmaceuticals has entered into a strategic research collaboration with Pfizer to develop drugs for orphan diseases, including lysosomal storage disorders. The estimated value of the collaboration to Zacharon is $210 million. The collaboration includes the development of compounds that may be discovered using Zacharon's innovative platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans.

More... »

Eisenhart named VP at Northwestern Mutual

Wednesday, April 6, 2011 01:18 PM

Joann Eisenhart, formerly senior vice president of human resources at Pfizer, has been named vice president of human resources of Milwaukee-based Northwestern Mutual.  Eisenhart also was named an executive officer. 

More... »

Pfizer plans to sell Capsugel unit

Tuesday, April 5, 2011 02:57 PM

Pfizer has plans to sell its Capsugel unit to an affiliate of investment firm Kohlberg Kravis Roberts (KKR) for nearly $2.4 billion in cash.  Pfizer’s plans to divest the division to narrow its business focus have been known for a while, according to Pharma Times.

More... »

Drugmakers may face FDA fines for slow efficacy confirmation in cancer drugs

Monday, March 28, 2011 01:04 PM

Winning early U.S. approval of promising cancer treatments could wind up costing drugmakers up to $10 million in fines if they don’t confirm their drugs’ effectiveness in follow-up studies within a restrictive timeframe, FDA officials said, according to a Bloomberg report.

More... »